| 前收市價 | 44.94 |
| 開市 | 43.65 |
| 買盤 | 42.11 x 200 |
| 賣出價 | 42.33 x 500 |
| 今日波幅 | 41.52 - 45.20 |
| 52 週波幅 | 7.10 - 50.78 |
| 成交量 | |
| 平均成交量 | 1,038,870 |
| 市值 | 2.305B |
| Beta 值 (5 年，每月) | 1.11 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | -2.25 |
| 業績公佈日 | 2024年8月08日 - 2024年8月12日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 48.88 |
Motley FoolCould This Stock Be the Next Biotech Buyout?
Vertex Pharmaceuticals' $4.9 billion purchase of Alpine Immune Sciences probably won't be the last acquisition of a company focused on kidney disease.
Barrons.comARS Pharmaceuticals, Nuvalent, and More Stocks See Action From Activist Investors
RA Capital increased its stake in biopharmaceutical firm ARS. Bain Capital lowered its stake in pharmaceutical firm Nuvalent.
InvestorPlace7 Stocks That Wall Street Analysts Are Loving in June
Peruse the Internet and you’ll eventually see opinions deriding top analyst recommended stocks as nothing but a clown show. Sure enough, many experts do get it wrong because let’s face it: if someone could truly predict the market consistently even 70% of the time, they wouldn’t be on TV. Instead, they would just use their system (quietly) to make an infinite amount of money. However, no such system exists and I don’t think I’m going out on a limb to suggest it will never exist. Fortunately, reg
